Charles River Laboratories International, Inc. (CRL) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Charles River Laboratories International, Inc. (CRL:NYSE), powered by AI.

Current Price
$187.51
P/E Ratio
-64.4
Market Cap
9.3B
Sector
Healthcare
What is the Charles River Laboratories International, Inc. stock price forecast?

Charles River Laboratories International, Inc. is currently trading at $187.51. View real-time AI analysis on Alpha Lenz.

What is Charles River Laboratories International, Inc. insider trading activity?

View the latest insider trading data for Charles River Laboratories International, Inc. on Alpha Lenz.

What is Charles River Laboratories International, Inc.'s P/E ratio?

Charles River Laboratories International, Inc.'s P/E ratio is -64.4.

Charles River Laboratories International, Inc.

NYSE · CRL
$187.51-0.55(-0.29%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Charles River Laboratories International, Inc.'s future dividend policy...
Alpha Chat Insight

Charles River Laboratories International, Inc. trades at a P/E of -64.4 (undervalued) with modest ROE of -4.4%.

Ask for details

Company Overview

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.

CEOMr. James C. Foster J.D.
SectorHealthcare
IndustryDiagnostics & Research
Employees18,700

Company Statistics

FY 2025

Profile

$9.29BMarket Cap
$4.02BRevenue
0.00Shares Out
18,700Employees

Margins

32.96%Gross
19.59%EBITDA
9.99%Operating
-2.48%Pre-Tax
-3.54%Net

Valuation

-64.39P/E
2.94P/B
2.31EV/Sales
14.87EV/EBITDA
17.92P/FCF

Growth (CAGR)

0.33%Rev 3Yr
6.55%Rev 5Yr
-14.90%Op Inc 3Yr
-1.50%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-1.94%ROA
-4.36%ROE
0.10%ROIC

Financial Health

$213.77MCash & Cash Equivalents
$3.71BNet Debt
122.20%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Charles River Laboratories International, Inc. (ticker: CRL) is a company listed on NYSE in the Healthcare sector (Diagnostics & Research). It has approximately 18,700 employees. Market cap is $9.3B.

The current price is $187.51 with a P/E ratio of -64.39x and P/B of 2.94x.

ROE is -4.36% and operating margin is 9.99%. Annual revenue is $4.0B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Charles River Laboratories International, Inc. (CRL) Stock Forecast 2026 $187.51 — Price, Financials & Analyst Targets | Alpha Lenz